Cargando…
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334187/ http://dx.doi.org/10.1186/1546-0096-6-S1-S3 |
| _version_ | 1782230609488248832 |
|---|---|
| author | Ruperto, N Lovell, DJ Cuttica, R Woo, P Espada, G Wouters, C Silverman, ED Balogh, Z Henrickson, M Davidson, J Foeldvari, I Imundo, L Simonini, G Oppermann, J Shen, YK Visvanathan, S Fasanmade, A Mendelsohn, A Martini, A Giannini, EH |
| author_facet | Ruperto, N Lovell, DJ Cuttica, R Woo, P Espada, G Wouters, C Silverman, ED Balogh, Z Henrickson, M Davidson, J Foeldvari, I Imundo, L Simonini, G Oppermann, J Shen, YK Visvanathan, S Fasanmade, A Mendelsohn, A Martini, A Giannini, EH |
| author_sort | Ruperto, N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3334187 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-33341872012-04-24 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension Ruperto, N Lovell, DJ Cuttica, R Woo, P Espada, G Wouters, C Silverman, ED Balogh, Z Henrickson, M Davidson, J Foeldvari, I Imundo, L Simonini, G Oppermann, J Shen, YK Visvanathan, S Fasanmade, A Mendelsohn, A Martini, A Giannini, EH Pediatr Rheumatol Online J Oral Presentation BioMed Central 2008-09-15 /pmc/articles/PMC3334187/ http://dx.doi.org/10.1186/1546-0096-6-S1-S3 Text en Copyright ©2008 Ruperto et al; licensee BioMed Central Ltd. |
| spellingShingle | Oral Presentation Ruperto, N Lovell, DJ Cuttica, R Woo, P Espada, G Wouters, C Silverman, ED Balogh, Z Henrickson, M Davidson, J Foeldvari, I Imundo, L Simonini, G Oppermann, J Shen, YK Visvanathan, S Fasanmade, A Mendelsohn, A Martini, A Giannini, EH 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title | 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title_full | 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title_fullStr | 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title_full_unstemmed | 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title_short | 2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension |
| title_sort | 2.3 long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (jra): findings from an open-label treatment extension |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334187/ http://dx.doi.org/10.1186/1546-0096-6-S1-S3 |
| work_keys_str_mv | AT ruperton 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT lovelldj 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT cutticar 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT woop 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT espadag 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT woutersc 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT silvermaned 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT baloghz 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT henricksonm 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT davidsonj 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT foeldvarii 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT imundol 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT simoninig 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT oppermannj 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT shenyk 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT visvanathans 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT fasanmadea 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT mendelsohna 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT martinia 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT gianninieh 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension AT 23longtermefficacyandsafetyofinfliximabplusmethotrexateforthetreatmentofpolyarticularcoursejuvenilerheumatoidarthritisjrafindingsfromanopenlabeltreatmentextension |